Fig. 3From: Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 studyOverview of the NORD-STAR study, treatment part 1. Abbreviations: TP1 treatment part 1, ACT aggressive conventional synthetic disease-modifying antirheumatic therapy, TNF tumor necrosis factor, ABA abatacept, TCZ tocilizumab, W weekBack to article page